ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. [electronic resource]
Producer: 20100930Description: e9013 p. digitalISSN:- 1932-6203
- Alternative Splicing
- Antineoplastic Agents, Hormonal -- pharmacology
- Blotting, Western
- Butadienes -- pharmacology
- Cell Line, Tumor
- Cell Membrane -- metabolism
- Cell Proliferation -- drug effects
- Chromones -- pharmacology
- Dose-Response Relationship, Drug
- Endometrial Neoplasms -- genetics
- Enzyme Activation -- drug effects
- Estrogen Receptor alpha -- agonists
- Estrogens -- pharmacology
- Extracellular Signal-Regulated MAP Kinases -- antagonists & inhibitors
- Female
- Humans
- Morpholines -- pharmacology
- Nitriles -- pharmacology
- Phosphatidylinositol 3-Kinases -- metabolism
- Phosphoinositide-3 Kinase Inhibitors
- Protein Isoforms -- agonists
- Proto-Oncogene Proteins c-akt -- metabolism
- Proto-Oncogene Proteins c-myc -- metabolism
- RNA Interference
- Signal Transduction -- drug effects
- Tamoxifen -- pharmacology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.